Sample | Title | Value | Rank |
GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 377.64 | 91 |
GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 464.304 | 92 |
GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 363.296 | 91 |
GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 376.279 | 91 |
GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 507.187 | 93 |
GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 500.163 | 93 |
GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 435.349 | 92 |
GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 450.883 | 92 |
GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 374.099 | 91 |
GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 400.075 | 91 |